In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Changing IP Landscape: Biopharma is the Battleground for Supreme Court Patent Assault

Executive Summary

The Supreme Court previously took a hands-off approach to IP cases, often going whole terms without deciding matters in this area, but that era appears to be coming to an end. The current justices have shown a renewed interest in patents, handing down one or more major decisions in each of the past few years. The life science industry will not only be affected by this shift; it is largely the means through which the Supreme Court is engineering this change in direction, particularly in the biopharma industry.

You may also be interested in...



Invalid! The Supreme Court Questions the Basis for Diagnostic Patents

The Supreme Court has decided to hear a case--LabCorp. vs Metabolite--that could invalidate patents based on the correlation between natural biological markers, like proteins or genes, and a disease. The case strikes at the heart of the new diagnostics start-ups-and could also invalidate a host of pharmaceutical IP strategies.

Supreme Court Puts Tools in Turmoil

In a blow for tool companies and a boost for drug developers, the Supreme Court in June held that drug companies could--in specific circumstances--use tool patents without paying for them. The problem: no one knows just how much protection the ruling affords. Even drug-developing biotechs, who now get a freer hand with other companies' tools, aren't universally happy with the ruling.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel